Barchart Research What to Expect from IMNM Earnings IMNM Generated August 11, 2026 Current Price $26.25 EPS Estimate $$-0.51 Consensus Rating Strong Buy Average Move 3.41% Immunome's Clinical Pipeline...
Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors Detailed Phase 3 RINGSIDE data...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the...
Barchart Research What to Expect from IMNM Earnings IMNM Generated August 4, 2026 Current Price $25.08 EPS Estimate $$-0.51 Consensus Rating Strong Buy Average Move 3.41% Immunome's First NDA Decision...
IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. The Phase 1 trial is designed to evaluate...
PDUFA target action date set for April 28, 2027 Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation...
IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation...
Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement...